=== Generating (published_papers) ===
=== Generating (teaching_experience) ===
=== Generating (misc) ===
=== Generating (research_projects) ===
=== Generating (books_etc) ===
=== Generating (awards) ===
=== Generating (presentations) ===
==== begin registerFile(/WWW/pub2/data/ERD/person/277628/researchmap/published_papers-propagate.jsonl) ====
line:1, {"insert":{"user_id":"7000022165","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/42244377","label":"url"},{"@id":"https://www.scopus.com/pages/publications/105040961381","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=464873","label":"url"}],"paper_title":{"en":"Three-dimensional cell-culture systems using nanofibrillated bacterial cellulose restores drug metabolism activity in HepG2 hepatocellular carcinoma cells","ja":"Three-dimensional cell-culture systems using nanofibrillated bacterial cellulose restores drug metabolism activity in HepG2 hepatocellular carcinoma cells"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Amorim Matsuo Cristina Nana"},{"name":"Akagi Shunsuke"},{"name":"Tajima Kenji"},{"name":"Takata Haruka"},{"name":"Serizawa Ryo"},{"name":"Matsushima Tokuo"},{"name":"Kusano Takatomo"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"赤木 俊介"},{"name":"Tajima Kenji"},{"name":"髙田 春風"},{"name":"Serizawa Ryo"},{"name":"Matsushima Tokuo"},{"name":"Kusano Takatomo"},{"name":"石田 竜弘"}]},"description":{"en":"Three-dimensional (3D) culture more faithfully reproducesin vivo-like cell interactions and functions than conventional two-dimensional (2D) monolayers. Although HepG2 cells are widely used in drug discovery, their 2D cultures exhibit low expression of drug-metabolizing enzymes such as cytochrome P450s (CYPs), limiting utility for toxicity and pharmacokinetic studies. Nano-fibrillated bacterial cellulose (NFBC) is a unique biomaterial that features exceptional homogeneity, high purity, and excellent biocompatibility. We recently employed two NFBC-based 3D culture systems: the Suspension and the OnGel methods. However, the capacity of NFBC to improve hepatocyte-specific functions has yet to be systematically explored. In this study, we aimed to establish a 3D culture platform for HepG2 cells using NFBC to restore hepatic functionality, and drug-metabolizing activity in particular, via comparison with conventional 2D monolayers. Both of these 3D culture systems produced viable HepG2 spheroids with good proliferation. Exploratory microarray profiling suggested broad upregulation of multiple absorption, distribution, metabolism and excretion (ADME) genes in the HepG2 spheroids. Among these, the enzyme Cytochrome P450 3A4 (CYP3A4) showed a significant increase in protein expression and in enzymatic activity in the HepG2 spheroids, which was functionally confirmed by acetaminophen (APAP) toxicity via its bioactivation into toxic metabolite. In addition, the HepG2 spheroids displayed reduced sensitivity to the anticancer drug doxorubicin compared to 2D monolayer. Collectively, these findings demonstrate that NFBC-based 3D culture systems effectively restore liver-specific functions in HepG2 cells, which results in HepG2 spheroids with metabolic competence and physiologically relevant drug responses, and could offer a promising tool for high-throughputin vitrodrug screening.","ja":"Three-dimensional (3D) culture more faithfully reproducesin vivo-like cell interactions and functions than conventional two-dimensional (2D) monolayers. Although HepG2 cells are widely used in drug discovery, their 2D cultures exhibit low expression of drug-metabolizing enzymes such as cytochrome P450s (CYPs), limiting utility for toxicity and pharmacokinetic studies. Nano-fibrillated bacterial cellulose (NFBC) is a unique biomaterial that features exceptional homogeneity, high purity, and excellent biocompatibility. We recently employed two NFBC-based 3D culture systems: the Suspension and the OnGel methods. However, the capacity of NFBC to improve hepatocyte-specific functions has yet to be systematically explored. In this study, we aimed to establish a 3D culture platform for HepG2 cells using NFBC to restore hepatic functionality, and drug-metabolizing activity in particular, via comparison with conventional 2D monolayers. Both of these 3D culture systems produced viable HepG2 spheroids with good proliferation. Exploratory microarray profiling suggested broad upregulation of multiple absorption, distribution, metabolism and excretion (ADME) genes in the HepG2 spheroids. Among these, the enzyme Cytochrome P450 3A4 (CYP3A4) showed a significant increase in protein expression and in enzymatic activity in the HepG2 spheroids, which was functionally confirmed by acetaminophen (APAP) toxicity via its bioactivation into toxic metabolite. In addition, the HepG2 spheroids displayed reduced sensitivity to the anticancer drug doxorubicin compared to 2D monolayer. Collectively, these findings demonstrate that NFBC-based 3D culture systems effectively restore liver-specific functions in HepG2 cells, which results in HepG2 spheroids with metabolic competence and physiologically relevant drug responses, and could offer a promising tool for high-throughputin vitrodrug screening."},"publication_date":"2026-06-05","publication_name":{"en":"Biomedical Materials","ja":"Biomedical Materials"},"volume":"21","number":"3","starting_page":"035025","ending_page":"035025","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1088/1748-605X/ae7243"],"issn":["1748-6041"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:2, {"insert":{"user_id":"7000022165","type":"published_papers","id":"52191923"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2013893","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/41565278","label":"url"},{"@id":"https://www.scopus.com/pages/publications/105028179972","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=459744","label":"url"}],"paper_title":{"en":"Ionic Liquids Composed of Lactic Acid and Trometamol Enhance the Oral Absorption of 10 kDa Dextran, as a Model Compound of Mid-Sized Molecules","ja":"Ionic Liquids Composed of Lactic Acid and Trometamol Enhance the Oral Absorption of 10 kDa Dextran, as a Model Compound of Mid-Sized Molecules"},"authors":{"en":[{"name":"Fukuda Shoichiro"},{"name":"Takata Haruka"},{"name":"Hayashi Ryo"},{"name":"Yamamoto Haruka"},{"name":"Nakae Takashi"},{"name":"Tatsumi Noboru"},{"name":"Hamamoto Hidetoshi"},{"name":"Kobayashi Shingo"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"福田 翔一郎"},{"name":"髙田 春風"},{"name":"林 涼羽"},{"name":"山本 遥香"},{"name":"Nakae Takashi"},{"name":"Tatsumi Noboru"},{"name":"Hamamoto Hidetoshi"},{"name":"小林 慎吾"},{"name":"安藤 英紀"},{"name":"石田 竜弘"}]},"description":{"en":"Oral administration is the preferred route for drug administration owing to a high level of patient compliance and suitability for long-term treatment. However, drugs with a molecular weight of >1000 Da such as peptide-based therapeutics generally exhibit poor absorption from the gastrointestinal tract. In this study, we evaluated the potential of ionic liquids to enhance the oral absorption of mid-sized molecules such as dextran, which has a size of 10 kDa. In this study, the ionic liquids we tested enhanced the oral absorption of 10 kDa mid-sized dextran. Among the ionic liquids we tested, d/l-Lactic acid-trometamol ([Lac][Tris])-based ionic liquids consistently yielded higher values for maximum concentration (Cmax; 153.9 ± 11.0 nmol/L) of dextran as well as for the area under the curve representing 0-2 h (AUC0-2 h; 228.9 ± 54.1 nmol × h/L) compared with that of the other ionic liquids tested. The [Lac][Tris] = 5 : 1 ionic liquid achieved relatively higher values for both Cmax and AUC0-2 h. Interestingly, the observed oral absorption enhancement effect by the [Lac][Tris] = 5 : 1 ionic liquid for mid-sized molecules depended on the concentration of dextran (10 kDa). These results show that ionic liquid formulations can overcome the intestinal barrier and lead to systemic absorption of mid-sized molecules with molecular weights. Although further optimizations aimed at translating ionic liquid technology to the oral delivery of peptide drugs must be required, our results could expand the utility and possibility of ionic liquids as an oral absorption enhancer for mid-sized molecules such as peptides.","ja":"Oral administration is the preferred route for drug administration owing to a high level of patient compliance and suitability for long-term treatment. However, drugs with a molecular weight of >1000 Da such as peptide-based therapeutics generally exhibit poor absorption from the gastrointestinal tract. In this study, we evaluated the potential of ionic liquids to enhance the oral absorption of mid-sized molecules such as dextran, which has a size of 10 kDa. In this study, the ionic liquids we tested enhanced the oral absorption of 10 kDa mid-sized dextran. Among the ionic liquids we tested, d/l-Lactic acid-trometamol ([Lac][Tris])-based ionic liquids consistently yielded higher values for maximum concentration (Cmax; 153.9 ± 11.0 nmol/L) of dextran as well as for the area under the curve representing 0-2 h (AUC0-2 h; 228.9 ± 54.1 nmol × h/L) compared with that of the other ionic liquids tested. The [Lac][Tris] = 5 : 1 ionic liquid achieved relatively higher values for both Cmax and AUC0-2 h. Interestingly, the observed oral absorption enhancement effect by the [Lac][Tris] = 5 : 1 ionic liquid for mid-sized molecules depended on the concentration of dextran (10 kDa). These results show that ionic liquid formulations can overcome the intestinal barrier and lead to systemic absorption of mid-sized molecules with molecular weights. Although further optimizations aimed at translating ionic liquid technology to the oral delivery of peptide drugs must be required, our results could expand the utility and possibility of ionic liquids as an oral absorption enhancer for mid-sized molecules such as peptides."},"publication_date":"2026-01","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"49","number":"1","starting_page":"141","ending_page":"148","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b25-00668"],"issn":["0918-6158"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:3, {"insert":{"user_id":"7000022165","type":"published_papers","id":"49778856"},"force":{"see_also":[{"@id":"http://id.ndl.go.jp/bib/034067974","label":"url"},{"@id":"https://cir.nii.ac.jp/crid/1390586136190861312/","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=426703","label":"url"}],"paper_title":{"en":"Blood sampling in mice and rats","ja":"マウスからの採血方法"},"authors":{"en":[{"name":"ANDO Hidenori"},{"name":"Matsuo Nana"},{"name":"Takata Haruka"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"松尾 アモリムクリスティーナ菜々"},{"name":"髙田 春風"},{"name":"石田 竜弘"}]},"publication_date":"2025-03-28","publication_name":{"en":"Drug Delivery System","ja":"Drug Delivery System"},"volume":"40","number":"2","starting_page":"156","ending_page":"158","languages":["jpn"],"referee":true,"identifiers":{"doi":["10.2745/dds.40.156"],"issn":["0913-5006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:4, {"insert":{"user_id":"7000022165","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=414763","label":"url"}],"paper_title":{"en":"Application of bacterial-derived long cellulose nanofiber to suspension culture of mammalian cells as a shear protectant","ja":"Application of bacterial-derived long cellulose nanofiber to suspension culture of mammalian cells as a shear protectant"},"authors":{"en":[{"name":"Kaneko Eiichiro"},{"name":"Tsujisaki Haruto"},{"name":"Fujiwara Masashi"},{"name":"ANDO Hidenori"},{"name":"Sato Yasushi"},{"name":"Ishida Tatsuhiro"},{"name":"Tani Hirofumi"},{"name":"Tajima Kenji"}],"ja":[{"name":"Kaneko Eiichiro"},{"name":"Tsujisaki Haruto"},{"name":"Fujiwara Masashi"},{"name":"安藤 英紀"},{"name":"Sato Yasushi"},{"name":"石田 竜弘"},{"name":"Tani Hirofumi"},{"name":"Tajima Kenji"}]},"publication_date":"2024-11","publication_name":{"en":"International Journal of Biological Macromolecules","ja":"International Journal of Biological Macromolecules"},"volume":"280","number":"3","starting_page":"135938","ending_page":"135938","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.ijbiomac.2024.135938"],"issn":["0141-8130"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:5, {"insert":{"user_id":"7000022165","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2012299","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/38813140","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85193252659","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=412140","label":"url"}],"paper_title":{"en":"Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases.","ja":"Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseases."},"authors":{"en":[{"name":"Hori Taiki"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Okada Naoto"},{"name":"Yamagami Hiroki"},{"name":"Yasui Saya"},{"name":"Hosoki Minae"},{"name":"Tojima Akihiro"},{"name":"Otoda Toshiki"},{"name":"Yuasa Tomoyuki"},{"name":"Aihara Ken-ichi"},{"name":"Takishita Makoto"},{"name":"Yoshida Sumiko"},{"name":"Abe Masahiro"},{"name":"Ishida Tatsuhiro"},{"name":"Nakamura Shingen"}],"ja":[{"name":"堀 太貴"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"岡田 直人"},{"name":"山上 紘規"},{"name":"Yasui Saya"},{"name":"Hosoki Minae"},{"name":"Tojima Akihiro"},{"name":"乙田 敏城"},{"name":"湯浅 智之"},{"name":"粟飯原 賢一"},{"name":"Takishita Makoto"},{"name":"吉田 守美子"},{"name":"安倍 正博"},{"name":"石田 竜弘"},{"name":"中村 信元"}]},"description":{"en":"The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition.","ja":"The effects of vaccination are modified by hematological and autoimmune diseases and/or treatment. Anti-SARS-CoV-2 mRNA vaccine contains polyethylene glycol (PEG), it is largely unknown whether PEG influences the effects of vaccination or induces a humoral response. This study examined whether anti-PEG antibodies before vaccination (pre-existing) influenced the acquisition of SARS-CoV-2 antibodies and evaluated the relationship between the development of anti-SARS-CoV-2 antibodies and anti-PEG antibodies after SARS-CoV-2 vaccination in hematological and autoimmune diseases. Anti-SARS-CoV-2 antibody IgG, anti-PEG IgG, and IgM titers were evaluated in patients with hematological and autoimmune diseases after the second dose of BNT162B2. Anti-PEG IgG and IgM titers were also measured before vaccination to examine changes after vaccination and the relationship with vaccine efficacy. In patients with hematological (n = 182) and autoimmune diseases (n = 96), anti-SARS-CoV-2 and anti-PEG antibody titers were evaluated after a median of 33 days from 2nd vaccination. The median anti-SARS-CoV-2 antibody titers were 1901 AU/mL and 3832 AU/mL in patients with hematological and autoimmune disease, respectively. Multiple regression analysis showed that age and days from 2nd vaccination were negatively associated with anti-SARS-CoV-2 antibody titers. Anti-CD20 antibody treatment was negatively correlated with anti-SARS-CoV-2 antibody titers in hematological disease, and C-reactive protein (CRP) was positively correlated with anti-SARS-CoV-2 antibody titers in autoimmune disease. Baseline anti-PEG antibody titers were significantly higher in patients with autoimmune disease but were not correlated with anti-SARS-CoV-2 antibody titers. Patients with increased anti-PEG IgG acquired higher anti-SARS-CoV-2 antibody titers in patients with autoimmune disease. Anti-SARS-CoV-2 antibody acquisition was suboptimal in patients with hematological disease, but both anti-SARS-CoV-2 antibody and anti-PEG IgG were acquired in patients with autoimmune disease, reflecting robust humoral immune response. Pre-existing anti-PEG antibody titers did not affect anti-SARS-CoV-2 antibody acquisition."},"publication_date":"2024-05-17","publication_name":{"en":"Heliyon","ja":"Heliyon"},"volume":"10","number":"10","starting_page":"e31489","ending_page":"e31489","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.heliyon.2024.e31489"],"issn":["2405-8440"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:6, {"insert":{"user_id":"7000022165","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=405320","label":"url"}],"paper_title":{"en":"Peritoneal B Cells Play a Role in The Production of Anti-Polyethylene Glycol (PEG) IgM Against Intravenously Injected siRNA-PEGylated Liposome Complexes","ja":"Peritoneal B Cells Play a Role in The Production of Anti-Polyethylene Glycol (PEG) IgM Against Intravenously Injected siRNA-PEGylated Liposome Complexes"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Amr S Abu Lila"},{"name":"Kitayama Yuka"},{"name":"Abe Ryo"},{"name":"Takata Haruka"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Amr S Abu Lila"},{"name":"北山 由佳"},{"name":"阿部 遼"},{"name":"髙田 春風"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"publication_date":"2024-02","publication_name":{"en":"Biological & Pharmaceutical Bulletin","ja":"Biological & Pharmaceutical Bulletin"},"volume":"47","number":"2","starting_page":"469","ending_page":"477","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1248/bpb.b23-00733"],"issn":["1347-5215"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:7, {"insert":{"user_id":"7000022165","type":"published_papers"},"similar_merge":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/37355210","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=402792","label":"url"}],"paper_title":{"en":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route","ja":"Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route"},"authors":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Yamade Rina"},{"name":"Elhewan Ali Emam Elsadek Emam Nehal"},{"name":"Emam Abdallah Emam Sherif"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"山出 莉奈"},{"name":"Nehal Emam Elsadek Emam Ali Elhewan"},{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Modifying the surface of nanoparticles with polyethylene glycol (PEG) is a commonly used approach for improving the in vitro stability of nanoparticles such as liposomes and increasing their circulation half-lives. We have demonstrated that, in certain conditions, an intravenous (i.v.) injection of PEGylated liposomes (PEG-Lip) induced anti-PEG IgM antibodies, which led to rapid clearance of second doses in mice. SARS-CoV-2 vaccines, composed of mRNA-containing PEGylated lipid nanoparticles, have been widely administered as intramuscular (i.m.) injections, so it is important to determine if PEGylated formulations can induce anti-PEG antibodies. If the favorable properties that PEGylation imparts to therapeutic nanoparticles are to be widely applicable this should apply to various routes of administration. However, there are few reports on the effect of different administration routes on the in vivo production of anti-PEG IgM. In this study, we investigated anti-PEG IgM production in mice following i.m., intraperitoneal (i.p.) and subcutaneous (s.c.) administration of PEG-Lip. PEG-Lip appeared to induce anti-PEG IgM by all the tested routes of administration, although the lipid dose causing maximum responses varied. Splenectomy attenuated the anti-PEG IgM production for all routes of administration, suggesting that splenic immune cells may have contributed to anti-PEG IgM production. Interestingly, in vitro experiments indicated that not only splenic cells but also cells in the peritoneal cavity induced anti-PEG IgM following incubation with PEG-Lip. These observations confirm previous experiments that have shown that measurable amounts of PEG-Lip administered i.p., i.m. or s.c. are absorbed to some extent into the blood circulation, where they can be distributed to the spleen and/or peritoneal cavity, and are recognized by B cells, triggering anti-PEG IgM production. The results obtained in this study have important implications for developing efficient PEGylated nanoparticular delivery system.","ja":"Modifying the surface of nanoparticles with polyethylene glycol (PEG) is a commonly used approach for improving the in vitro stability of nanoparticles such as liposomes and increasing their circulation half-lives. We have demonstrated that, in certain conditions, an intravenous (i.v.) injection of PEGylated liposomes (PEG-Lip) induced anti-PEG IgM antibodies, which led to rapid clearance of second doses in mice. SARS-CoV-2 vaccines, composed of mRNA-containing PEGylated lipid nanoparticles, have been widely administered as intramuscular (i.m.) injections, so it is important to determine if PEGylated formulations can induce anti-PEG antibodies. If the favorable properties that PEGylation imparts to therapeutic nanoparticles are to be widely applicable this should apply to various routes of administration. However, there are few reports on the effect of different administration routes on the in vivo production of anti-PEG IgM. In this study, we investigated anti-PEG IgM production in mice following i.m., intraperitoneal (i.p.) and subcutaneous (s.c.) administration of PEG-Lip. PEG-Lip appeared to induce anti-PEG IgM by all the tested routes of administration, although the lipid dose causing maximum responses varied. Splenectomy attenuated the anti-PEG IgM production for all routes of administration, suggesting that splenic immune cells may have contributed to anti-PEG IgM production. Interestingly, in vitro experiments indicated that not only splenic cells but also cells in the peritoneal cavity induced anti-PEG IgM following incubation with PEG-Lip. These observations confirm previous experiments that have shown that measurable amounts of PEG-Lip administered i.p., i.m. or s.c. are absorbed to some extent into the blood circulation, where they can be distributed to the spleen and/or peritoneal cavity, and are recognized by B cells, triggering anti-PEG IgM production. The results obtained in this study have important implications for developing efficient PEGylated nanoparticular delivery system."},"publication_date":"2023-08","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"360","starting_page":"285","ending_page":"292","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2023.06.027"],"issn":["1873-4995"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:8, {"insert":{"user_id":"7000022165","type":"published_papers","id":"41053444"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393469","label":"url"}],"paper_title":{"en":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","ja":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice"},"authors":{"en":[{"name":"Ibrahim Mohamed"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Elgarhy Omar Helmy"},{"name":"Sarhan Hatem A"},{"name":"Hussein Amal K"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"Ibrahim Mohamed"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"Elgarhy Omar Helmy"},{"name":"Sarhan Hatem A"},{"name":"Hussein Amal K"},{"name":"石田 竜弘"}]},"publication_date":"2023-02-01","publication_name":{"en":"Journal of Controlled Release","ja":"Journal of Controlled Release"},"volume":"354","starting_page":"260","ending_page":"267","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.jconrel.2023.01.012"],"issn":["0168-3659"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:9, {"insert":{"user_id":"7000022165","type":"published_papers","id":"41042825"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/36708147","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85147389240","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=393449","label":"url"}],"paper_title":{"en":"Clinical impact of anti-polyethylene glycol (PEG) antibody in haematological patients administered PEGylated-granulocyte colony-stimulating factor","ja":"Clinical impact of anti-polyethylene glycol (PEG) antibody in haematological patients administered PEGylated-granulocyte colony-stimulating factor"},"authors":{"en":[{"name":"Okada Naoto"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Nakamura Shingen"},{"name":"Goda Mitsuhiro"},{"name":"Abe Masahiro"},{"name":"Kitahara Takashi"},{"name":"Ishida Tatsuhiro"},{"name":"Ishizawa Keisuke"}],"ja":[{"name":"Okada Naoto"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"中村 信元"},{"name":"Goda Mitsuhiro"},{"name":"Abe Masahiro"},{"name":"Kitahara Takashi"},{"name":"石田 竜弘"},{"name":"Ishizawa Keisuke"}]},"description":{"en":"Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half-life and efficacy. We previously reported that the PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti-PEG antibody titers and the clinical impact of PEG-G-CSF in 19 hematological patients. A gradual decrease of anti-PEG antibody titers from baseline was observed after PEG-G-CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG-G-CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut-off values of pretreated anti-PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti-PEG antibody titers above this cut-off value (P = .033). An enzyme-linked immunosorbent assay revealed that some anti-PEG antibodies in patients with anti-PEG antibody titers above the cut-off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti-PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti-PEG antibodies and the development of adverse events after PEG-G-CSF administration.","ja":"Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half-life and efficacy. We previously reported that the PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti-PEG antibody titers and the clinical impact of PEG-G-CSF in 19 hematological patients. A gradual decrease of anti-PEG antibody titers from baseline was observed after PEG-G-CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG-G-CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut-off values of pretreated anti-PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti-PEG antibody titers above this cut-off value (P = .033). An enzyme-linked immunosorbent assay revealed that some anti-PEG antibodies in patients with anti-PEG antibody titers above the cut-off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti-PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti-PEG antibodies and the development of adverse events after PEG-G-CSF administration."},"publication_date":"2023-01-28","publication_name":{"en":"Clinical Pharmacology in Drug Development","ja":"Clinical Pharmacology in Drug Development"},"volume":"12","number":"8","starting_page":"826","ending_page":"831","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1002/cpdd.1225"],"issn":["2160-7648"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:10, {"insert":{"user_id":"7000022165","type":"published_papers","id":"33577516"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2009199","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=381696","label":"url"}],"paper_title":{"en":"Efficient construction of the hexacyclic ring core of palau'amine: the pKa concept for proceeding with unfavorable equilibrium reactions","ja":"Efficient construction of the hexacyclic ring core of palau'amine: the pKa concept for proceeding with unfavorable equilibrium reactions"},"authors":{"en":[{"name":"Ohashi Eisaku"},{"name":"Karanjit Sangita"},{"name":"Nakayama Atsushi"},{"name":"Takeuchi Kohei"},{"name":"Emam E Sherif"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Namba Kosuke"}],"ja":[{"name":"大橋 栄作"},{"name":"カランジット サンギータ"},{"name":"中山 淳"},{"name":"竹内 公平"},{"name":"Sherif Emam Abdallah Emam"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"難波 康祐"}]},"publication_date":"2021-08-11","publication_name":{"en":"Chemical Science","ja":"Chemical Science"},"volume":"12","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1039/D1SC03260G"],"issn":["2041-6539"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:11, {"insert":{"user_id":"7000022165","type":"published_papers","id":"30512778"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/32700691","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=366739","label":"url"}],"paper_title":{"en":"Utilization of Click Chemistry to Study the Effect of Poly(ethylene) Glycol Molecular Weight on the Self-Assembly of PEGylated Gambogic Acid Nanoparticles for the Treatment of Rheumatoid Arthritis","ja":"Utilization of Click Chemistry to Study the Effect of Poly(ethylene) Glycol Molecular Weight on the Self-Assembly of PEGylated Gambogic Acid Nanoparticles for the Treatment of Rheumatoid Arthritis"},"authors":{"en":[{"name":"Nguyen A"},{"name":"ANDO Hidenori"},{"name":"Böttger R"},{"name":"Viswanadham K K"},{"name":"Rouhollahi E"},{"name":"Ishida Tatsuhiro"},{"name":"Li S"}],"ja":[{"name":"Nguyen A"},{"name":"安藤 英紀"},{"name":"Böttger R"},{"name":"Viswanadham K K"},{"name":"Rouhollahi E"},{"name":"石田 竜弘"},{"name":"Li S"}]},"description":{"en":"Many small-molecule drugs exhibit poor aqueous solubility, and various approaches have been developed to improve their solubility and delivery. Chemical conjugation of an insoluble drug to a hydrophilic polymer can promote the self-assembly into nanoparticles (NPs) to increase the apparent solubility and improve the pharmacokinetics of the drug. However, majority of the reports in the field disclose only one composition of the conjugate, while accumulating evidence suggests that structure-activity relationship (SAR) studies must be conducted to identify an optimal construct. In this study, we employed a click chemistry platform to robustly conjugate short-chain methoxypolyethylene glycol (mPEG) of three different molecular weights to a small molecule anti-inflammatory drug, gambogic acid (GA), and studied the SAR. NPs formed with mPEG550 and mPEG5000, referred to as NP-550 and NP-5000, respectively, had larger mean diameters (130.0 ± 16.9 nm and 143.0 ± 0.1 nm, respectively) and higher critical micellar concentrations (CMCs, 9.5 μg mL-1 and 10.5 μg mL-1, respectively) compared to NPs formed with mPEG2000 (NP-2000, mean diameter = 97.8 ± 5.0 nm and CMC = 6.6 μg mL-1). NP-2000 and NP-5000 did not cause significant hemolytic toxicity, whereas NP-550 and free GA induced 90% and 60% hemolysis, respectively. NP-2000 was selected for further studies due to its improved safety, small size and low CMC. In cultured inflammatory macrophages, NP-2000 exhibited activity comparable to free GA in suppressing tumor necrosis factor-α. In mice, NP-2000 showed 185-fold improved drug exposure compared to free GA after intraperitoneal delivery. Treatment with free GA showed little anti-inflammatory activity compared to vehicle control in a murine model of rheumatoid arthritis. In contrast, NP-2000 significantly reduced the paw inflammation by 27% from day 15 to day 29. NP-2000 showed no visible signs of toxicity in mice, while free GA elicited significant irritation at the injection site. Our work emphasizes the importance of performing SAR studies for developing an optimal drug-polymer conjugate for self-assembly into NPs. We also demonstrate a unique application of click chemistry to robustly synthesize a small library of conjugates for the SAR study.","ja":"Many small-molecule drugs exhibit poor aqueous solubility, and various approaches have been developed to improve their solubility and delivery. Chemical conjugation of an insoluble drug to a hydrophilic polymer can promote the self-assembly into nanoparticles (NPs) to increase the apparent solubility and improve the pharmacokinetics of the drug. However, majority of the reports in the field disclose only one composition of the conjugate, while accumulating evidence suggests that structure-activity relationship (SAR) studies must be conducted to identify an optimal construct. In this study, we employed a click chemistry platform to robustly conjugate short-chain methoxypolyethylene glycol (mPEG) of three different molecular weights to a small molecule anti-inflammatory drug, gambogic acid (GA), and studied the SAR. NPs formed with mPEG550 and mPEG5000, referred to as NP-550 and NP-5000, respectively, had larger mean diameters (130.0 ± 16.9 nm and 143.0 ± 0.1 nm, respectively) and higher critical micellar concentrations (CMCs, 9.5 μg mL-1 and 10.5 μg mL-1, respectively) compared to NPs formed with mPEG2000 (NP-2000, mean diameter = 97.8 ± 5.0 nm and CMC = 6.6 μg mL-1). NP-2000 and NP-5000 did not cause significant hemolytic toxicity, whereas NP-550 and free GA induced 90% and 60% hemolysis, respectively. NP-2000 was selected for further studies due to its improved safety, small size and low CMC. In cultured inflammatory macrophages, NP-2000 exhibited activity comparable to free GA in suppressing tumor necrosis factor-α. In mice, NP-2000 showed 185-fold improved drug exposure compared to free GA after intraperitoneal delivery. Treatment with free GA showed little anti-inflammatory activity compared to vehicle control in a murine model of rheumatoid arthritis. In contrast, NP-2000 significantly reduced the paw inflammation by 27% from day 15 to day 29. NP-2000 showed no visible signs of toxicity in mice, while free GA elicited significant irritation at the injection site. Our work emphasizes the importance of performing SAR studies for developing an optimal drug-polymer conjugate for self-assembly into NPs. We also demonstrate a unique application of click chemistry to robustly synthesize a small library of conjugates for the SAR study."},"publication_date":"2020-08-21","publication_name":{"en":"Biomaterials Science","ja":"Biomaterials Science"},"volume":"8","number":"16","starting_page":"4626","ending_page":"4637","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1039/d0bm00711k"],"issn":["2047-4849"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:12, {"insert":{"user_id":"7000022165","type":"published_papers","id":"30512799"},"force":{"see_also":[{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/29054682","label":"url"},{"@id":"https://www.scopus.com/pages/publications/85032786660","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=334214","label":"url"}],"paper_title":{"en":"Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity","ja":"Liposomalization of oxaliplatin induces skin accumulation of it, but negligible skin toxicity"},"authors":{"en":[{"name":"Nishida Kentaro"},{"name":"Kashiwagi Misaki"},{"name":"Shiba Shunsuke"},{"name":"Muroki Kiwamu"},{"name":"Ohishi Akihiro"},{"name":"Doi Yusuke"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Nagasawa Kazuki"}],"ja":[{"name":"Nishida Kentaro"},{"name":"Kashiwagi Misaki"},{"name":"Shiba Shunsuke"},{"name":"Muroki Kiwamu"},{"name":"Ohishi Akihiro"},{"name":"土井 祐輔"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"Nagasawa Kazuki"}]},"description":{"en":"Liposomalization causes alteration of the pharmacokinetics of encapsulated drugs, and allows delivery to tumor tissues through passive targeting via an enhanced permeation and retention (EPR) effect. PEGylated liposomal doxorubicin (Doxil(®), Lipo-DXR), a representative liposomal drug, is well-known to reduce cardiotoxicity and increase the anti-tumor activity of DXR, but to induce the hand-foot syndrome (HFS) as a result of skin DXR accumulation, which is one of its severe adverse effects. We have developed a new liposomal preparation of oxaliplatin (l-OHP), an important anti-tumor drug for treatment of colorectal cancer, using PEGylated liposomes (Lipo-l-OHP), and showed that Lipo-l-OHP exhibits increased anti-tumor activity in tumor-bearing mice compared to the original preparation of l-OHP. However, whether Lipo-l-OHP causes HFS-like skin toxicity similar to Lipo-DXR remains to be determined. Administration of Lipo-l-OHP promoted accumulation of platinum in rat hind paws, however, it caused negligible morphological and histological alterations on the plantar surface of the paws. Administration of DiI-labeled empty PEGylated liposomes gave almost the same distribution profile of dyes into the dermis of hind paws with DXR as in the case of Lipo-DXR. Treatment with Lipo-l-OHP, Lipo-DXR, DiI-labeled empty PEGylated liposomes or empty PEGylated liposomes caused migration of CD68(+) macrophages into the dermis of hind paws. These findings suggest that the skin toxicity on administration of liposomalized drugs is reflected in the proinflammatory characteristics of encapsulated drugs, and indicate that Lipo-l-OHP with a higher anti-cancer effect and no HFS may be an outstanding l-OHP preparation leading to an improved quality of life of cancer patients.","ja":"Liposomalization causes alteration of the pharmacokinetics of encapsulated drugs, and allows delivery to tumor tissues through passive targeting via an enhanced permeation and retention (EPR) effect. PEGylated liposomal doxorubicin (Doxil(®), Lipo-DXR), a representative liposomal drug, is well-known to reduce cardiotoxicity and increase the anti-tumor activity of DXR, but to induce the hand-foot syndrome (HFS) as a result of skin DXR accumulation, which is one of its severe adverse effects. We have developed a new liposomal preparation of oxaliplatin (l-OHP), an important anti-tumor drug for treatment of colorectal cancer, using PEGylated liposomes (Lipo-l-OHP), and showed that Lipo-l-OHP exhibits increased anti-tumor activity in tumor-bearing mice compared to the original preparation of l-OHP. However, whether Lipo-l-OHP causes HFS-like skin toxicity similar to Lipo-DXR remains to be determined. Administration of Lipo-l-OHP promoted accumulation of platinum in rat hind paws, however, it caused negligible morphological and histological alterations on the plantar surface of the paws. Administration of DiI-labeled empty PEGylated liposomes gave almost the same distribution profile of dyes into the dermis of hind paws with DXR as in the case of Lipo-DXR. Treatment with Lipo-l-OHP, Lipo-DXR, DiI-labeled empty PEGylated liposomes or empty PEGylated liposomes caused migration of CD68(+) macrophages into the dermis of hind paws. These findings suggest that the skin toxicity on administration of liposomalized drugs is reflected in the proinflammatory characteristics of encapsulated drugs, and indicate that Lipo-l-OHP with a higher anti-cancer effect and no HFS may be an outstanding l-OHP preparation leading to an improved quality of life of cancer patients."},"publication_date":"2017-12-15","publication_name":{"en":"Toxicology and Applied Pharmacology","ja":"Toxicology and Applied Pharmacology"},"volume":"337","starting_page":"76","ending_page":"84","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1016/j.taap.2017.10.006"],"issn":["1096-0333"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
line:13, {"insert":{"user_id":"7000022165","type":"published_papers","id":"30512800"},"force":{"see_also":[{"@id":"https://tokushima-u.repo.nii.ac.jp/records/2005523","label":"url"},{"@id":"https://www.ncbi.nlm.nih.gov/pubmed/28643902","label":"url"},{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=325157","label":"url"}],"paper_title":{"en":"Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model","ja":"Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model"},"authors":{"en":[{"name":"Shimizu Taro"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"Nishio Miho"},{"name":"Doi Yusuke"},{"name":"ANDO Hidenori"},{"name":"Ukawa Masami"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Amr Selim Ahmed Ali Abu Lila"},{"name":"西尾 美穂"},{"name":"土井 祐輔"},{"name":"安藤 英紀"},{"name":"鵜川 真実"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"description":{"en":"Immune modulation of the tumor microenvironment has been reported to participate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we reported that liposomal encapsulation of oxaliplatin (l-OHP) within PEGylated liposomes conferred a superior antitumor efficacy to free l-OHP in murine colorectal carcinoma-bearing mice through permitting preferential accumulation of the encapsulated drug within tumor tissue. However, the contribution of the immune-modulatory properties of liposomal l-OHP and/or free l-OHP to the overall antitumor efficacy was not elucidated. In the present study, therefore, we investigated the effect of liposomal encapsulation of l-OHP within PEGylated liposomes on the antitumor immunity in both immunocompetent and immunodeficient mice. Liposomal l-OHP significantly suppressed the growth of tumors implanted in immunocompetent mice, but not in immunodeficient mice. In immunocompetent mice, liposomal l-OHP increased the tumor MHC-1 level and preserved antitumor immunity through decreasing the number of immune suppressor cells, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, which collectively suppress CD8(+) T cell-mediated tumor cells killing. In contrast, free l-OHP ruined antitumor immunity. These results suggest that the antitumor efficacy of liposomal l-OHP is attributed, on the one hand, to its immunomodulatory effect on tumor immune microenvironment that is superior to that of free l-OHP, and on the other hand, to its direct cytotoxic effect on tumor cells.","ja":"Immune modulation of the tumor microenvironment has been reported to participate in the therapeutic efficacy of many chemotherapeutic agents. Recently, we reported that liposomal encapsulation of oxaliplatin (l-OHP) within PEGylated liposomes conferred a superior antitumor efficacy to free l-OHP in murine colorectal carcinoma-bearing mice through permitting preferential accumulation of the encapsulated drug within tumor tissue. However, the contribution of the immune-modulatory properties of liposomal l-OHP and/or free l-OHP to the overall antitumor efficacy was not elucidated. In the present study, therefore, we investigated the effect of liposomal encapsulation of l-OHP within PEGylated liposomes on the antitumor immunity in both immunocompetent and immunodeficient mice. Liposomal l-OHP significantly suppressed the growth of tumors implanted in immunocompetent mice, but not in immunodeficient mice. In immunocompetent mice, liposomal l-OHP increased the tumor MHC-1 level and preserved antitumor immunity through decreasing the number of immune suppressor cells, including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, which collectively suppress CD8(+) T cell-mediated tumor cells killing. In contrast, free l-OHP ruined antitumor immunity. These results suggest that the antitumor efficacy of liposomal l-OHP is attributed, on the one hand, to its immunomodulatory effect on tumor immune microenvironment that is superior to that of free l-OHP, and on the other hand, to its direct cytotoxic effect on tumor cells."},"publication_date":"2017-07-14","publication_name":{"en":"Cancer Science","ja":"Cancer Science"},"volume":"108","number":"9","starting_page":"1864","ending_page":"1869","languages":["eng"],"referee":true,"identifiers":{"doi":["10.1111/cas.13305"],"issn":["1349-7006"]},"published_paper_type":"scientific_journal"},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/277628/researchmap/published_papers-propagate.jsonl, GYMyjaABRJbN-uhaqHCH) ====
==== begin registerFile(/WWW/pub2/data/ERD/person/277628/researchmap/presentations-propagate.jsonl) ====
line:1, {"insert":{"user_id":"7000022165","type":"presentations","id":"30512817"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=333514","label":"url"}],"presentation_title":{"en":"An industrial method of manufacturing a novel RNAi anticancer drug, DFP-10825, for the treatment of peritoneal disseminated gastric cancer","ja":"An industrial method of manufacturing a novel RNAi anticancer drug, DFP-10825, for the treatment of peritoneal disseminated gastric cancer"},"presenters":{"en":[{"name":"Ishida Tatsuhiro"},{"name":"ANDO Hidenori"},{"name":"Fukushima M"},{"name":"Huang C.L"},{"name":"Wada H"}],"ja":[{"name":"石田 竜弘"},{"name":"安藤 英紀"},{"name":"Fukushima M"},{"name":"Huang C.L"},{"name":"Wada H"}]},"event":{"en":"AACR Annual Meeting 2017","ja":"AACR Annual Meeting 2017"},"publication_date":"2017-04-05","languages":["eng"],"location":{"en":"Washington, D.C.","ja":"Washington, D.C."},"is_international_presentation":true},"priority":"input_data"}
line:2, {"insert":{"user_id":"7000022165","type":"presentations","id":"50729220"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=446107","label":"url"}],"presentation_title":{"en":"筋肉内投与されたmRNA/LNPによる抗スパイク抗体誘導に抗PEG抗体が及ぼす影響","ja":"筋肉内投与されたmRNA/LNPによる抗スパイク抗体誘導に抗PEG抗体が及ぼす影響"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Abe Shunji"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"阿部 舜史"},{"name":"安藤 英紀"},{"name":"石田 竜弘"}]},"event":{"en":"第32回DDSカンファランス","ja":"第32回DDSカンファランス"},"publication_date":"2024-09-13","languages":["jpn"],"location":{"en":"Shizuoka","ja":"静岡"},"is_international_presentation":false},"priority":"input_data"}
line:3, {"insert":{"user_id":"7000022165","type":"presentations","id":"39818980"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391654","label":"url"}],"presentation_title":{"en":"毛髪中に含まれる超硫黄分子の検出および機能解明","ja":"毛髪中に含まれる超硫黄分子の検出および機能解明"},"presenters":{"en":[{"name":"Hirai Takeru"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishida Tatsuhiro"},{"name":"Ishima Yu"}],"ja":[{"name":"平井 傑琉"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"石田 竜弘"},{"name":"異島 優"}]},"event":{"en":"フォーラム2022:衛生薬学・環境トキシコロジー","ja":"フォーラム2022:衛生薬学・環境トキシコロジー"},"publication_date":"2022-08","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
line:4, {"insert":{"user_id":"7000022165","type":"presentations","id":"39818981"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391651","label":"url"}],"presentation_title":{"en":"血中の抗PEG抗体が筋肉内投与後のmRNA搭載LNPのタンパク質発現に与える影響に関する検討","ja":"血中の抗PEG抗体が筋肉内投与後のmRNA搭載LNPのタンパク質発現に与える影響に関する検討"},"presenters":{"en":[{"name":"Abe Shunji"},{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"阿部 舜史"},{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"遺伝子・デリバリー研究会第20回夏期セミナー","ja":"遺伝子・デリバリー研究会第20回夏期セミナー"},"publication_date":"2022-08-26","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:5, {"insert":{"user_id":"7000022165","type":"presentations","id":"39818982"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=391650","label":"url"}],"presentation_title":{"en":"siRNA搭載PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討","ja":"siRNA搭載PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Ueda Hiro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"上田 大"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"遺伝子・デリバリー研究会第20回夏期セミナー","ja":"遺伝子・デリバリー研究会第20回夏期セミナー"},"publication_date":"2022-08-26","languages":["jpn"],"location":{"en":"Tokyo","ja":"東京"},"is_international_presentation":false},"priority":"input_data"}
line:6, {"insert":{"user_id":"7000022165","type":"presentations","id":"35250416"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382783","label":"url"}],"presentation_title":{"en":"抗原封入リポソームの脾臓免疫による抗体誘導に関するPEG末端構造の影響","ja":"抗原封入リポソームの脾臓免疫による抗体誘導に関するPEG末端構造の影響"},"presenters":{"en":[{"name":"Yamamoto Shunto"},{"name":"ANDO Hidenori"},{"name":"前田 典之"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"山本 舜人"},{"name":"安藤 英紀"},{"name":"前田 典之"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:7, {"insert":{"user_id":"7000022165","type":"presentations","id":"35250417"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382782","label":"url"}],"presentation_title":{"en":"表面物性の異なるナノフィブリル化バクテリアセルロースを用いたパクリタキセル製剤の開発と腹膜播種治療評価","ja":"表面物性の異なるナノフィブリル化バクテリアセルロースを用いたパクリタキセル製剤の開発と腹膜播種治療評価"},"presenters":{"en":[{"name":"Takata Masaki"},{"name":"ANDO Hidenori"},{"name":"Akagi Shunsuke"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"高田 正希"},{"name":"安藤 英紀"},{"name":"赤木 俊介"},{"name":"田島 健次"},{"name":"松島 得雄"},{"name":"草野 貴友"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:8, {"insert":{"user_id":"7000022165","type":"presentations","id":"35250418"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382780","label":"url"}],"presentation_title":{"en":"重曹経口投与による腫瘍内微小環境中性化にともなう遺伝子発現解析","ja":"重曹経口投与による腫瘍内微小環境中性化にともなう遺伝子発現解析"},"presenters":{"en":[{"name":"Uehara Riku"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"上原 陸"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:9, {"insert":{"user_id":"7000022165","type":"presentations","id":"35250419"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382779","label":"url"}],"presentation_title":{"en":"Sulfane sulfur付加型HSAを用いた還元ストレス誘導を介するがん治療戦略","ja":"Sulfane sulfur付加型HSAを用いた還元ストレス誘導を介するがん治療戦略"},"presenters":{"en":[{"name":"Matsuo Nana"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"松尾 菜々"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:10, {"insert":{"user_id":"7000022165","type":"presentations","id":"35250420"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=382777","label":"url"}],"presentation_title":{"en":"核酸搭載PEG修飾カチオン性リポソームによる抗PEG抗体および抗核酸抗体誘導に及ぼすガングリオシド修飾の影響","ja":"核酸搭載PEG修飾カチオン性リポソームによる抗PEG抗体および抗核酸抗体誘導に及ぼすガングリオシド修飾の影響"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Qelliny Milad"},{"name":"Takata Haruka"},{"name":"Hiro UEDA"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"Qelliny Milad"},{"name":"髙田 春風"},{"name":"上田 大"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会","ja":"第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会"},"publication_date":"2021-11-08","languages":["jpn"],"location":{"en":"Matsuyama","ja":"松山"},"is_international_presentation":false},"priority":"input_data"}
line:11, {"insert":{"user_id":"7000022165","type":"presentations","id":"32883796"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376519","label":"url"}],"presentation_title":{"en":"新規脾臓免疫で誘導した抗体の多様性および結合性の評価","ja":"新規脾臓免疫で誘導した抗体の多様性および結合性の評価"},"presenters":{"en":[{"name":"ANDO Hidenori"},{"name":"Yamaguchi Sesshu"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"安藤 英紀"},{"name":"山口 雪洲"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-30","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:12, {"insert":{"user_id":"7000022165","type":"presentations","id":"32883797"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376517","label":"url"}],"presentation_title":{"en":"脾臓辺縁帯B細胞を標的としたペプチド封入リポソームによる免疫誘導に関する検討","ja":"脾臓辺縁帯B細胞を標的としたペプチド封入リポソームによる免疫誘導に関する検討"},"presenters":{"en":[{"name":"Shimizu Taro"},{"name":"Shimazaki Yuna"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"清水 太郎"},{"name":"島崎 優奈"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-30","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:13, {"insert":{"user_id":"7000022165","type":"presentations","id":"32883798"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376522","label":"url"}],"presentation_title":{"en":"投与経路が及ぼすPEG修飾リポソーム投与時の抗PEG抗体誘導に与える影響に関する検討","ja":"投与経路が及ぼすPEG修飾リポソーム投与時の抗PEG抗体誘導に与える影響に関する検討"},"presenters":{"en":[{"name":"Takata Haruka"},{"name":"Shimizu Taro"},{"name":"Kawaguchi Yoshino"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"髙田 春風"},{"name":"清水 太郎"},{"name":"川口 桂乃"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"第37回日本DDS学会学術集会","ja":"第37回日本DDS学会学術集会"},"publication_date":"2021-06-29","languages":["jpn"],"location":{"en":"Chiba","ja":"千葉"},"is_international_presentation":false},"priority":"input_data"}
line:14, {"insert":{"user_id":"7000022165","type":"presentations","id":"32883799"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=376515","label":"url"}],"presentation_title":{"en":"イオン液体を用いたIL-23 特異的siRNAの経皮送達はイミキモド誘発乾癬モデルマウスの皮膚症状を改善する","ja":"イオン液体を用いたIL-23 特異的siRNAの経皮送達はイミキモド誘発乾癬モデルマウスの皮膚症状を改善する"},"presenters":{"en":[{"name":"Sakamoto Chika"},{"name":"Shimizu Taro"},{"name":"ANDO Hidenori"},{"name":"Ishima Yu"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"坂元 智香"},{"name":"清水 太郎"},{"name":"安藤 英紀"},{"name":"異島 優"},{"name":"小林 勝則"},{"name":"石橋 賢樹"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"石田 竜弘"}]},"event":{"en":"日本核酸医薬学会第6回年会","ja":"日本核酸医薬学会第6回年会"},"publication_date":"2021-06-27","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:15, {"insert":{"user_id":"7000022165","type":"presentations","id":"32512547"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375622","label":"url"}],"presentation_title":{"en":"様々なヒト血清アルブミン受容体を介した薬物キャリアの開発","ja":"様々なヒト血清アルブミン受容体を介した薬物キャリアの開発"},"presenters":{"en":[{"name":"Hashimoto Aiko"},{"name":"Hama Maichi"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 愛子"},{"name":"濱 眞壱"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:16, {"insert":{"user_id":"7000022165","type":"presentations","id":"32512548"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375621","label":"url"}],"presentation_title":{"en":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序解明","ja":"致死性エンドトキシンショックに対するヒト血清アルブミンの治療効果の機序解明"},"presenters":{"en":[{"name":"Mukai Aina"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"向井 愛菜"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:17, {"insert":{"user_id":"7000022165","type":"presentations","id":"32512549"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375620","label":"url"}],"presentation_title":{"en":"紫外線による皮膚角質中に含まれる活性イオウ分子種の変動","ja":"紫外線による皮膚角質中に含まれる活性イオウ分子種の変動"},"presenters":{"en":[{"name":"Hashimoto Reina"},{"name":"Ishima Yu"},{"name":"ANDO Hidenori"},{"name":"Shimizu Taro"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"橋本 怜奈"},{"name":"異島 優"},{"name":"安藤 英紀"},{"name":"清水 太郎"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:18, {"insert":{"user_id":"7000022165","type":"presentations","id":"32512550"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375619","label":"url"}],"presentation_title":{"en":"イオン液体を基剤としたLixisenatide製剤の開発と腸管吸収評価","ja":"イオン液体を基剤としたLixisenatide製剤の開発と腸管吸収評価"},"presenters":{"en":[{"name":"Sunami Takaya"},{"name":"ANDO Hidenori"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"角南 尚哉"},{"name":"安藤 英紀"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"辰巳 昇"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:19, {"insert":{"user_id":"7000022165","type":"presentations","id":"32512551"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=375618","label":"url"}],"presentation_title":{"en":"イオン液体を用いた難経口吸収性化合物の腸管吸収促進効果の検討","ja":"イオン液体を用いた難経口吸収性化合物の腸管吸収促進効果の検討"},"presenters":{"en":[{"name":"Atsuya MARUYAMA"},{"name":"ANDO Hidenori"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"Shimizu Taro"},{"name":"Ishima Yu"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"丸山 敦也"},{"name":"安藤 英紀"},{"name":"中江 崇"},{"name":"三輪 泰司"},{"name":"濱本 英利"},{"name":"清水 太郎"},{"name":"異島 優"},{"name":"石田 竜弘"}]},"event":{"en":"日本薬剤学会第36年会","ja":"日本薬剤学会第36年会"},"publication_date":"2021-05-14","languages":["jpn"],"location":{"en":"Tokushima","ja":"徳島"},"is_international_presentation":false},"priority":"input_data"}
line:20, {"insert":{"user_id":"7000022165","type":"presentations","id":"30512845"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=352028","label":"url"}],"presentation_title":{"en":"新規蛍光プローブIndocyanine green (ICG) 標識Dasatinibを用いた消化管間質腫瘍 (GIST) の近赤外蛍光 イメージング.","ja":"新規蛍光プローブIndocyanine green (ICG) 標識Dasatinibを用いた消化管間質腫瘍 (GIST) の近赤外蛍光 イメージング."},"presenters":{"en":[{"name":"Fujimoto Shota"},{"name":"Muguruma Naoki"},{"name":"Nakao Michiyasu"},{"name":"ANDO Hidenori"},{"name":"Miyamoto Yoshihiko"},{"name":"Okamoto Koichi"},{"name":"Sato Yasushi"},{"name":"Ishida Tatsuhiro"},{"name":"Sano Shigeki"},{"name":"Takayama Tetsuji"}],"ja":[{"name":"藤本 将太"},{"name":"六車 直樹"},{"name":"中尾 允泰"},{"name":"安藤 英紀"},{"name":"宮本 佳彦"},{"name":"岡本 耕一"},{"name":"佐藤 康史"},{"name":"石田 竜弘"},{"name":"佐野 茂樹"},{"name":"高山 哲治"}]},"event":{"en":"第14回日本分子イメージング学会総会・学術集会","ja":"第14回日本分子イメージング学会総会・学術集会"},"publication_date":"2019-05-23","languages":["jpn"],"location":{"en":"Sapporo","ja":"札幌"},"is_international_presentation":false},"priority":"input_data"}
line:21, {"insert":{"user_id":"7000022165","type":"presentations","id":"30512849"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=349643","label":"url"}],"presentation_title":{"en":"尿アルカリ化を指標とした腫瘍内環境の改善","ja":"尿アルカリ化を指標とした腫瘍内環境の改善"},"presenters":{"en":[{"name":"ANDO Hidenori"}],"ja":[{"name":"安藤 英紀"}]},"event":{"en":"第2回徳島大学統合的がん創薬研究クラスター合同ミーティング","ja":"第2回徳島大学統合的がん創薬研究クラスター合同ミーティング"},"publication_date":"2019-02-04","languages":["jpn"],"location":{"en":"Awaji","ja":"淡路"},"is_international_presentation":false},"priority":"input_data"}
line:22, {"insert":{"user_id":"7000022165","type":"presentations","id":"30512880"},"force":{"see_also":[{"@id":"https://web.db.tokushima-u.ac.jp/cgi-bin/edb_browse?EID=305589","label":"url"}],"presentation_title":{"en":"Intelligent RNA expression devise(iRed)による標的遺伝子抑制に関する検討","ja":"Intelligent RNA expression devise(iRed)による標的遺伝子抑制に関する検討"},"presenters":{"en":[{"name":"Kinjoh Nozomi"},{"name":"ANDO Hidenori"},{"name":"Saito-Tarashima Noriko"},{"name":"Minakawa Noriaki"},{"name":"Ishida Tatsuhiro"}],"ja":[{"name":"金城 望"},{"name":"安藤 英紀"},{"name":"田良島 典子"},{"name":"南川 典昭"},{"name":"石田 竜弘"}]},"event":{"en":"第37回生体膜と薬物の相互作用シンポジウム","ja":"第37回生体膜と薬物の相互作用シンポジウム"},"publication_date":"2015-11-20","languages":["jpn"],"location":{"en":"Kumamoto","ja":"熊本"},"is_international_presentation":false},"priority":"input_data"}
==== end registerFile(/WWW/pub2/data/ERD/person/277628/researchmap/presentations-propagate.jsonl, I4MyjaABRJbN-uha93KS) ====
====== BulkResult(7000022165, GYMyjaABRJbN-uhaqHCH) : Begin ======
--- error
{"code":304,"status":"completion","start_datetime":"2026-09-10T21:21:44Z","end_datetime":"2026-09-10T21:21:44Z","estimated_end_datetime":"2026-09-10T21:21:45Z","total_items":13}

--- success
{"code":304,"status":"completion","start_datetime":"2026-09-10T21:21:44Z","end_datetime":"2026-09-10T21:21:44Z","estimated_end_datetime":"2026-09-10T21:21:45Z","total_items":13}
{"no":1,"line":1,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"54161308","link":"https://api.researchmap.jp/canther/published_papers/54161308","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=54161308]。"}]}
{"no":1,"line":2,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"52191923","link":"https://api.researchmap.jp/canther/published_papers/52191923","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =52191923]。"}]}
{"no":1,"line":3,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"49778856","link":"https://api.researchmap.jp/canther/published_papers/49778856","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =49778856]。"}]}
{"no":1,"line":4,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"47951872","link":"https://api.researchmap.jp/canther/published_papers/47951872","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=47951872]。"}]}
{"no":1,"line":5,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"47227175","link":"https://api.researchmap.jp/canther/published_papers/47227175","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=47227175]。"}]}
{"no":1,"line":6,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"45725404","link":"https://api.researchmap.jp/canther/published_papers/45725404","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=45725404]。"}]}
{"no":1,"line":7,"code":304,"action":"insert","action_type":"similar_merge","priority":"input_data","type":"published_papers","id":"42806444","link":"https://api.researchmap.jp/canther/published_papers/42806444","messages":[{"code":304,"message":"not_similar_modified","message_description":"本人相当が登録した類似の業績が存在したため、更新しませんでした[id=42806444]。"}]}
{"no":1,"line":8,"code":304,"action":"insert","action_type":"force","type":"published_papers","id":"41053444","link":"https://api.researchmap.jp/canther/published_papers/41053444","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=41053444]。"}]}
{"no":1,"line":9,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"41042825","link":"https://api.researchmap.jp/canther/published_papers/41042825","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =41042825]。"}]}
{"no":1,"line":10,"code":304,"action":"insert","action_type":"force","type":"published_papers","id":"33577516","link":"https://api.researchmap.jp/canther/published_papers/33577516","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=33577516]。"}]}
{"no":1,"line":11,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"30512778","link":"https://api.researchmap.jp/canther/published_papers/30512778","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =30512778]。"}]}
{"no":1,"line":12,"code":304,"action":"insert","action_type":"force","type":"published_papers","id":"30512799","link":"https://api.researchmap.jp/canther/published_papers/30512799","messages":[{"code":304,"message":"not_modified","message_description":"本人相当が登録した既存データが存在したため、更新しませんでした[id=30512799]。"}]}
{"no":1,"line":13,"code":304,"action":"insert","action_type":"merge","type":"published_papers","id":"30512800","link":"https://api.researchmap.jp/canther/published_papers/30512800","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =30512800]。"}]}
====== BulkResult(7000022165, GYMyjaABRJbN-uhaqHCH) : End ======
====== BulkResult(7000022165, I4MyjaABRJbN-uha93KS) : Begin ======
--- error
{"code":304,"status":"completion","start_datetime":"2026-09-10T21:22:04Z","end_datetime":"2026-09-10T21:22:04Z","estimated_end_datetime":"2026-09-10T21:22:05Z","total_items":22}

--- success
{"code":304,"status":"completion","start_datetime":"2026-09-10T21:22:04Z","end_datetime":"2026-09-10T21:22:04Z","estimated_end_datetime":"2026-09-10T21:22:05Z","total_items":22}
{"no":1,"line":1,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"30512817","link":"https://api.researchmap.jp/canther/presentations/30512817","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =30512817]。"}]}
{"no":1,"line":2,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"50729220","link":"https://api.researchmap.jp/canther/presentations/50729220","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =50729220]。"}]}
{"no":1,"line":3,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39818980","link":"https://api.researchmap.jp/canther/presentations/39818980","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39818980]。"}]}
{"no":1,"line":4,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39818981","link":"https://api.researchmap.jp/canther/presentations/39818981","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39818981]。"}]}
{"no":1,"line":5,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"39818982","link":"https://api.researchmap.jp/canther/presentations/39818982","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =39818982]。"}]}
{"no":1,"line":6,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"35250416","link":"https://api.researchmap.jp/canther/presentations/35250416","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =35250416]。"}]}
{"no":1,"line":7,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"35250417","link":"https://api.researchmap.jp/canther/presentations/35250417","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =35250417]。"}]}
{"no":1,"line":8,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"35250418","link":"https://api.researchmap.jp/canther/presentations/35250418","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =35250418]。"}]}
{"no":1,"line":9,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"35250419","link":"https://api.researchmap.jp/canther/presentations/35250419","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =35250419]。"}]}
{"no":1,"line":10,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"35250420","link":"https://api.researchmap.jp/canther/presentations/35250420","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =35250420]。"}]}
{"no":1,"line":11,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32883796","link":"https://api.researchmap.jp/canther/presentations/32883796","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32883796]。"}]}
{"no":1,"line":12,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32883797","link":"https://api.researchmap.jp/canther/presentations/32883797","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32883797]。"}]}
{"no":1,"line":13,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32883798","link":"https://api.researchmap.jp/canther/presentations/32883798","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32883798]。"}]}
{"no":1,"line":14,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32883799","link":"https://api.researchmap.jp/canther/presentations/32883799","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32883799]。"}]}
{"no":1,"line":15,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32512547","link":"https://api.researchmap.jp/canther/presentations/32512547","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32512547]。"}]}
{"no":1,"line":16,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32512548","link":"https://api.researchmap.jp/canther/presentations/32512548","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32512548]。"}]}
{"no":1,"line":17,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32512549","link":"https://api.researchmap.jp/canther/presentations/32512549","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32512549]。"}]}
{"no":1,"line":18,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32512550","link":"https://api.researchmap.jp/canther/presentations/32512550","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32512550]。"}]}
{"no":1,"line":19,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"32512551","link":"https://api.researchmap.jp/canther/presentations/32512551","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =32512551]。"}]}
{"no":1,"line":20,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"30512845","link":"https://api.researchmap.jp/canther/presentations/30512845","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =30512845]。"}]}
{"no":1,"line":21,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"30512849","link":"https://api.researchmap.jp/canther/presentations/30512849","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =30512849]。"}]}
{"no":1,"line":22,"code":304,"action":"insert","action_type":"merge","type":"presentations","id":"30512880","link":"https://api.researchmap.jp/canther/presentations/30512880","messages":[{"code":304,"message":"not_changed","message_description":"変更はないので、更新されませんでした[id =30512880]。"}]}
====== BulkResult(7000022165, I4MyjaABRJbN-uha93KS) : End ======